ArticleFrontiers in oncology2022

Investigational cyclin-dependent kinase 4/6 inhibitor GLR2007 demonstrates activity against isocitrate dehydrogenase wild-type glioblastoma and other solid tumors in mice xenograft models.

Lei Yin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.